An interventional study of Non-invasive skin AGE measurements in Chronic Intestinal Insufficiency, Advanced Glycation and Products and Parenteral Nutrition, sponsored by University Hospital, Bordeaux. Recruiting at 3 sites in France. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Metabolic Diseases with a site in France — 17 open to participants now, 22 under way, 6 of them phase 3. Metabolic Diseases · France.
Among the 55 studies in Metabolic Diseases with a site in France, this one is the 25th largest by planned enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2026, is one of 14 with no phase, reaches primary completion later than 7 of the 21 other live ones, and was the 53rd registered.
763 studies on the registry are indexed under Metabolic Diseases; 192 are open to participants now.
Browse Metabolic Diseases studies →17 of the 55 studies in Metabolic Diseases with a site in France are open now. Recruiting first, the newest first:
Pfizer · Sites in France, United States, Brazil and 8 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 7–20
iECURE, Inc. · Sites in France, United States, United Kingdom
Ages 7 mo–15 mo
Kyowa Kirin Co., Ltd. · Sites in France, United States, Canada and 2 more countries
Ages 18–65
Hoffmann-La Roche · Sites in France, United States, Argentina and 22 more countries
Ages 18–75
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 133 Metabolic Diseases studies recruiting now, 47 (35%) set no upper age limit and 63 (47%) stop at 75 or younger; 38 take children under 18; 50 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 15
First in 2003; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 50 across 525 interventional studies indexed under Metabolic Diseases.
Median enrollment 79 across the 38 interventional studies, 500 across the 17 observational. Of the 30 that completed or were terminated, 8 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 55 have an industry lead sponsor. The 10 most frequent:
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
University Hospital, Bordeaux has 2 studies filed under Metabolic Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Metabolic Diseases with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04654000University Hospital, LilleRheopheresis as Adjuvant Treatment of Calciphylaxis | 2027-04 |
| NCT07392801University Hospital, BordeauxAGE Accumulation in Patients on Long-term Parenteral Nutrition | 2027-07 |
| NCT04159103ModernaTX, Inc.Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia | 2027-08-31 |
| NCT05318196University Hospital, ToulouseMolecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies in Metabolic Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective and observational study aims to evaluate the accumulation of advanced glycation end-products (AGEs) in adult and pediatric patients starting long-term parenteral nutrition, by non-invasive skin AGE measurements over a 12-month follow-up.
Advanced Glycation End-products (AGEs) result from non-enzymatic glycation of proteins, lipids, or amino acids, and accumulate progressively with age, hyperglycemia, and oxidative stress. Their accumulation is associated with metabolic and cardiovascular complications in chronic diseases. Preliminary data suggest that patients on long-term parenteral nutrition may experience increased AGE accumulation due to high intravenous glucose exposure. However, prospective data evaluating AGE kinetics from the initiation of parenteral nutrition are lacking.
Skin AGE levels will be measured non-invasively at baseline, 6 months, and 12 months using the AGE Reader© device. Nutrition bag samples will be analyzed for AGE content via HPLC-MS.
Patients will be monitored during routine consultations every 6 months. Biological metabolic parameters (HbA1c, fructosamine, lipid profile), nutritional data, and 3-day dietary records will be collected at each time point. Samples from parenteral nutrition bags will be frozen at -20°C or colder and analyzed centrally after the last patient visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Observational follow-up of patients starting long-term parenteral nutrition
Other: Non-invasive skin AGE measurements
Non-invasive skin AGE measurements at baseline, 6 and 12 months; collection and analysis of parenteral nutrition bag samples; routine metabolic assessments; dietary records, glucose holter, plasma glycated hemoglobin and fructosamine assays.
Skin AGE levels
Change in skin AGE levels between baseline and 12 months after initiation of parenteral nutrition (Visit M12).
Time frame: Baseline, 12 months
Advanced Glycation End-products
Compare skin AGE (Advanced Glycation End-products) levels with Age levels in parenteral nutrition bags (M6)
Time frame: 6 months
Risk factors
Search for risk factors for AGE accumulation linked to dietary habits
Time frame: Baseline, 6 months and 12 months
Skin AGE and metabolic/cardiovascular status
To investigate whether there is an association between skin AGE levels and the metabolic and cardiovascular status of patients.
Time frame: Baseline, 6 months and 12 months
AGE and hyperglycaemic episodes
To investigate whether there is an association between skin AGE levels and the number, duration and intensity of hyperglycaemic episodes during parenteral nutrition infusion.
Time frame: Baseline, 6 months and 12 months
Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.
Of 182 non-industry interventional studies with no phase under Metabolic Diseases, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 12 months is below that.
Counting every sponsor, half of 201 studies reached it within 22 months; a quarter within 10 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →